Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
R3i & IAS Press Conference
Paris, France, 1 September 2019
The International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation announce a Joint Consensus Statement on Selective Peroxisome Proliferator Activated Receptor alpha Modulators (SPPARMα)
Watch Press Conference Webcasts...
R3i editorial
19 March 2020

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Lowering triglycerides or low-density lipoprotein cholesterol: which provides greater clinical benefit?Read more...

Treatment guidelines prioritise low-density lipoprotein cholesterol (LDL-C) as the primary lipid target for intervention to prevent atherosclerotic cardiovascular disease (ASCVD). The evidence for this is indisputable.
Yet even with highly efficacious LDL-C lowering, patients at high and very high-risk experience recurrent cardiovascular events. This persistent residual vascular risk implies the need to consider other targets...
landmark study
19 March 2020

More insights from REDUCE-IT: Impact on total cardiovascular events Read more...

Cardiovascular outcomes trials involving lipid-lowering treatment in patients with atherosclerotic cardiovascular disease (ASCVD) have conventionally chosen the time to first nonfatal or fatal event as the primary endpoint. However, the time to first event may not be the best representation of the total burden of...
focus on...
19 March 2020

Meta-analysis: Association between triglyceride lowering and reduction of cardiovascular risk Read more...

Evidence from observational studies, genetic analyses and Mendelian randomization studies support a causal association between TG and risk for atherosclerotic cardiovascular disease (ASCVD).1 Data from clinical trials of therapies that lower TG, including fibrates, niacin and omega-3 fatty acids, however, have been less definitive.2-10 While...
recent publication

New review: Triglycerides and residual riskRead more...

Consideration of triglycerides level, a surrogate for triglyceride-rich lipoproteins and their remnants, as a contributor to lipid-related residual cardiovascular risk,...
recent publication

Novel approaches in hypertriglyceridemia: dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonistRead more...

A preclinical study has highlighted potential for a dual apolipoprotein (apo) C-II mimetic and apoC-III antagonist in the management of...
recent publication

Alirocumab in atherogenic dyslipidemiaRead more...

This post hoc analysis from the ODYSSEY DM-DYSLIPIDEMIA trial investigated the efficacy of alirocumab, a PCSK9 monoclonal antibody, in the...
recent publication

Omega-3 supplementation and cardiovascular diseaseRead more...

Marine omega-3 supplementation lowers the risk of cardiovascular events, including cardiovascular death, but dose is critical. This is the conclusion...
recent publication

News with pemafibrate, a novel SPPARMĪ± agentRead more...

Professors Shizuya Yamashita, Daisaku Masuda and Yuji Matsuzawa overview preclinical data and evidence from clinical trials with pemafibrate in this...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARĪ±Ms in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.